3 Stocks Estimated To Be Undervalued In September 2026
Solstice Advanced Materials, AbbVie, and Oracle are identified as potentially undervalued stocks. Solstice trades at $61.37 with a 38.7% discount to fair value, expecting 22% annual earnings growth. AbbVie trades at $260.21 with a 42.5% discount, forecasting 23.4% growth. Oracle trades at $154.04 with a 29.8% discount, anticipating 24.7% revenue growth.
How this was made
The 30-second read
Why it matters
No new corporate disclosures; the piece aggregates existing data and forecasts.
Market read
Provides a thematic view of perceived undervaluation but lacks actionable new information.
What to watch
Debt levels, competitive pressures, and macro‑economic headwinds could limit upside.
Background
The article is a valuation roundup from Simply Wall St, presenting three U.S. stocks deemed undervalued based on cash‑flow analysis.
Ticker impact
AbbVie is presented with a 42.5% discount to fair value and mentions positive trial results for etentamig.
Minimal, since the information is not a first report.
The article repeats known trial outcomes and valuation metrics.
Oracle is listed with a 29.8% discount to fair value and projected 24.7% revenue growth.
Low, lacking a fresh catalyst.
No new corporate announcement; merely restates existing estimates.
Market effects
Highlights potential undervaluation in specialty chemicals, biopharma, and enterprise software sectors.
U.S. market focus; no regional shift indicated.
Limited, as the article does not introduce new global macro factors.
Counterpoint
Valuation gaps may reflect underlying risks not captured in cash‑flow models.
Key entities
- companySolstice Advanced Materials
Specialty chemicals and advanced materials firm.
- companyAbbVie
Biopharmaceutical company.
- companyOracle
Enterprise software and cloud services provider.
